Dyne Therapeutics grabs $115M to ramp up muscle illness pipeline

1
65

Dyne Therapeutics is again on the VC effectively—this time, it’s elevating $115 million to bankroll a pipeline of remedies for muscle illnesses together with its lead packages for Duchenne muscular dystrophy and two different muscle-wasting illnesses.

The highest-up comes from Dyne’s backers Forbion, MPM Capital and Atlas Enterprise—which based, seeded and incubated the corporate—in addition to from newcomers Vida Ventures, Surveyor Capital, Wellington Administration Firm, Logos Capital and Franklin Templeton.

“We’re excited to have such robust assist from excellent new and present traders who share the Dyne crew’s imaginative and prescient of constructing the world’s main muscle illness firm,” Dyne CEO Joshua Brumm mentioned in a press release. “Importantly, this capital permits us to leverage our FORCE platform and advance our pipeline of recent oligonucleotide therapeutics aimed toward remodeling the lives of people dwelling with critical muscle illnesses.”

Sponsored by Biotech Primer

September 2-3, 2020 Reside, On-line Course: Biopharma Income Forecasting that Drives Resolution Making and Investments

Turn out to be fluent within the core components of income forecasting together with epidemiology, aggressive assessments, market share task and pricing. Let Biotech Primer’s dynamic trade specialists educate you find out how to assess the worth of latest therapies.

RELATED: Dyne begins life with $50M, large biopharma names for muscle illness work

The FORCE platform permits Dyne to conjugate antibodies to oligonucleotides—brief DNA or RNA molecules—to deal with critical muscle illnesses. An antibody brings the payload to muscle cells, the place the oligonucleotide binds with RNA that drives illness development and degrades it.

RELATED: Muscle dysfunction biotech Avidity goals for the clinic with $100M IPO

The corporate has three preclinical-stage property—along with its Duchenne program, it’s engaged on remedies for myotonic dystrophy Kind 1 (DM1), a muscle losing dysfunction attributable to a mutation within the DMPK gene, and facioscapulohumeral muscular dystrophy (FSHD), which is attributable to genetic modifications in chromosome four and primarily impacts muscle groups within the face, shoulder blades and higher arms. It’s taking a look at cardiac and metabolic muscle illnesses in its discovery-stage work.

Dyne isn’t the one participant engaged on antibody-oligonucleotide conjugates. Avidity Biosciences can also be utilizing the strategy to deal with muscle illnesses. The corporate raised $100 million in enterprise funding late final 12 months and filed to lift $100 million in its IPO in Might, earlier than closing its itemizing at $298 million. It expects its first program, in myotonic dystrophy Kind 1, to enter the clinic in 2021.

Attaching medicine to antibodies to use their selective nature isn’t new—a number of firms are engaged on antibody-drug conjugates to ship cell-killing medicine to most cancers cells with out harming wholesome tissue. However Avidity and Dyne imagine that utilizing oligonucleotides might work even higher.

1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here